These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 22278138)

  • 21. What is the role of direct renin inhibitors in the treatment of the hypertensive diabetic patient?
    de la Sierra A; Salazar J
    Adv Ther; 2011 Sep; 28(9):716-27. PubMed ID: 21809181
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of antihypertensive therapy on glucose, insulin metabolism, left ventricular diastolic dysfunction and renin system in overweight and obese hypertensives.
    De Rosa ML; Musella F; Ilardi F; D'Amore C; Luciano R; Maresca F
    J Renin Angiotensin Aldosterone Syst; 2014 Jun; 15(2):196-204. PubMed ID: 23396551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination renin-angiotensin system blockade with the renin inhibitor aliskiren in hypertension.
    Doulton TW; MacGregor GA
    J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):185-9. PubMed ID: 19617273
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aliskiren as add-on therapy in the treatment of hypertensive diabetic patients inadequately controlled with valsartan/HCT combination: a placebo-controlled study.
    Drummond W; Sirenko YM; Ramos E; Baek I; Keefe DL
    Am J Cardiovasc Drugs; 2011 Oct; 11(5):327-33. PubMed ID: 21846154
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aliskiren in the management of hypertension.
    Barrios V; Escobar C
    Am J Cardiovasc Drugs; 2010; 10(6):349-58. PubMed ID: 21090828
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aliskiren for renin inhibition: a new class of antihypertensives.
    Van Tassell BW; Munger MA
    Ann Pharmacother; 2007 Mar; 41(3):456-64. PubMed ID: 17341529
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selective renin inhibition in obese hypertensive patients: perspectives from tissue penetration.
    Virdis A; Grassi G
    J Hypertens; 2012 Mar; 30(3):470-1. PubMed ID: 22317993
    [No Abstract]   [Full Text] [Related]  

  • 28. Aliskiren: new drug. Arterial hypertension: no evidence of clinical efficacy.
    Prescrire Int; 2008 Apr; 17(94):47-50. PubMed ID: 18516803
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term safety, tolerability, and antihypertensive efficacy of aliskiren, an oral direct renin inhibitor, in Japanese patients with hypertension.
    Kushiro T; Itakura H; Abo Y; Gotou H; Terao S; Keefe DL
    Hypertens Res; 2009 Mar; 32(3):169-75. PubMed ID: 19262478
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aliskiren: a review of its use in the management of hypertension.
    Frampton JE; Curran MP
    Drugs; 2007; 67(12):1767-92. PubMed ID: 17683174
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aliskiren: an oral renin inhibitor for the treatment of hypertension.
    Lam S; Choy M
    Cardiol Rev; 2007; 15(6):316-23. PubMed ID: 18090068
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Advantages and limitations of renin inhibition with aliskiren].
    Azizi M; Frank M; Steichen O; Blanchard A
    Ann Pharm Fr; 2011 May; 69(3):142-50. PubMed ID: 21570538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics and pharmacodynamics of aliskiren, an oral direct renin inhibitor.
    Buczko W; Hermanowicz JM
    Pharmacol Rep; 2008; 60(5):623-31. PubMed ID: 19066408
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.
    Pool JL; Schmieder RE; Azizi M; Aldigier JC; Januszewicz A; Zidek W; Chiang Y; Satlin A
    Am J Hypertens; 2007 Jan; 20(1):11-20. PubMed ID: 17198906
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Direct inhibition of renin: a physiological approach to treat hypertension and cardiovascular disease.
    Ram CV
    Future Cardiol; 2009 Sep; 5(5):453-65. PubMed ID: 19715410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine.
    Nussberger J; Aubert JF; Bouzourene K; Pellegrin M; Hayoz D; Mazzolai L
    Hypertension; 2008 May; 51(5):1306-11. PubMed ID: 18391092
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparison of the antihypertensive and anti-inflammatory effects of aliskiren and ramipril add-on therapy in peritoneal dialysis patients--a pilot open label study.
    Makówka A; Olejniczak-Fortak M; Nowicki M
    Kidney Blood Press Res; 2012; 36(1):18-25. PubMed ID: 22777192
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aliskiren reduces sympathetic nerve activity and blood pressure in chronic kidney disease patients.
    Siddiqi L; Oey PL; Blankestijn PJ
    Nephrol Dial Transplant; 2011 Sep; 26(9):2930-4. PubMed ID: 21467128
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity.
    Dalla Vestra M; Simioni N; Masiero A
    Minerva Endocrinol; 2009 Dec; 34(4):333-8. PubMed ID: 20046162
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aliskiren for the treatment of essential hypertension under real-life practice conditions: design and baseline data of the prospective 3A registry.
    Zeymer U; Dechend R; Deeg E; Kaiser E; Senges J; Pittrow D; Schmieder R;
    Int J Clin Pract; 2012 Mar; 66(3):251-61. PubMed ID: 22321062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.